

TABLE OF CONTENTS

Book 9

Preface	i
Editorial Board	ii
Book 9 Panel	iii
Disclosure of Potential Conflicts of Interest	ix
Continuing Education and Program Evaluation Instructions	x
Roles of ACCP and BPS	xiii

Chronic Illnesses IV

ASTHMA

Learning Objectives	1
Introduction	1
Pathophysiology	2
Definition	2
Etiology	2
Clinical Characteristics	2
Perimenstrual	2
Diagnosis and Assessment	2
Epidemiology	3
Prognosis and Natural History	3
Therapeutic Goals and Outcomes	4
Quality Patient Care	4
Pharmacotherapy Update	4
Long-acting Inhaled β_2 -agonists	4
Salmeterol	4
Formoterol	5
Inhaled Corticosteroids	5
Leukotriene Receptor Antagonists	5
Montelukast Age Indication	5
Intravenous Montelukast	5

Zafirlukast Age Indication	6
Anti-immunoglobulin E Therapy	6
Omalizumab	6
Short-acting Inhaled β_2 -agonist	6
Levalbuterol	6
Allergen Immunotherapy	6
Other Treatments	6
Treatment Plans	7
Chronic Therapy	7
Acute Therapy	10
NAEPP Guidelines	10
Antibiotic Drug Use	10
Special Populations	10
Pregnancy	10
Devices	10
Metered-dose Inhalers	10
Dry Powder Inhalers	11
Monitoring	11
Written Action Plans	16
Peak Flow and Symptom-based Action Plans	16
Exhaled Nitric Oxide	17
Pharmacoeconomic and Quality of Life Assessments	17
Patient Education	17
Quality Improvements	18
Conclusion	18
Annotated Bibliography	18
Self-Assessment Questions	21

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Learning Objectives	27
Introduction	27
Epidemiology of COPD	27
Impact	27
Risk Factors	28
Pathogenesis and Pathophysiology	28
Diagnosis and Severity Classification	30
Spirometry	30
Clinical Presentation and Assessment	30
Quality Patient Care	31

Goals	31
Nonpharmacological Management	31
Patient Education	31
Pulmonary Rehabilitation	31
Risk Factor Reduction	32
Immunizations	33
Correcting Physiologic Abnormalities	33
Surgery	34
Pharmacotherapy	34
Outcome Measures	35
Bronchodilators	35
β_2 -Agonists	36
Anticholinergics	37
Methylxanthines	38
Inhaled Corticosteroids	38
Combination of Inhaled Long-acting β_2 -agonists and Inhaled Corticosteroids	38
Combinations of Long-acting Bronchodilators	39
AAT Replacement Therapy	39
Phosphodiesterase 4 Inhibitors	39
Other Investigational Therapies	39
Treatment Plan	39
Therapeutic Goals	40
Approach to Pharmacotherapy	40
Monitoring and Documentation	41
Patient Education and Counseling	41
Communicating with Patients and Families	41
Efficiency, Efficacy, and Effectiveness of Treatment Plan	41
Medication Use Process	42
Managing Specific Situations	42
Exacerbations	42
Pathophysiology	42
Classifying Severity	43
Treatment	43
Conclusion	44
Annotated Bibliography	44
Self-Assessment Questions	47

Mini Mental State Examination	59
AD Cooperative Study-Activities of Daily Living Inventory	59
Global Deterioration Scale	59
Clinical Dementia Rating	59
Severe Impairment Battery	59
Clinician's Interview Based Assessment of Change-Plus	59
Neuropsychiatric Inventory	59
Progressive Deterioration Scale	59
Pharmacotherapy	60
Cholinesterase Inhibitors	60
Donepezil	60
Galantamine	64
Rivastigmine	65
Choosing a Cholinesterase Inhibitor	65
Cost-effectiveness of Cholinesterase Inhibitors	66
NMDA Receptor Antagonist	67
Cost-effectiveness of Memantine	69
Switching Therapy	69
Combination Therapy	69
Discontinuation of Therapy	70
Investigational Therapies	70
Antiamyloid	70
Antioxidant Therapy	70
Nonsteroidal Anti-inflammatory Drugs	70
Estrogens	70
Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors (Statins)	71
Management of Behavioral Disturbances	71
Investigational Therapies	72
Pharmaceutical Care	72
Conclusion	73
Annotated Bibliography	73
Self-Assessment Questions	75

Pediatrics I

CONGENITAL HEART DEFECTS AND SUPRAVENTRICULAR TACHYCARDIA IN CHILDREN	
Learning Objectives	83
Introduction	83
Perinatal Circulation	84
Fetal Circulation	84
Circulatory Adaptations at Birth	85
Congenital Heart Defects	85
Left-to-right Shunts	86
Ventricular Septal Defect	86
Patent Ductus Arteriosus	87
Cyanotic Heart Lesions	87
Tetralogy of Fallot	87
Transposition of the Great Arteries	90
Obstructive Lesions	91
Coarctation of the Aorta	92
Hypoplastic Left Heart Syndrome	93
Pharmacological Management	98

Cardiac Rhythm Disorders	103	RSV Immune Globulin and Palivizumab	124
Supraventricular Tachycardia	104	American Academy of Pediatrics	
Atrioventricular Reentrant Tachycardia	104	Recommendations	125
Atrioventricular Nodal Reentrant Tachycardia	105	Use of Prophylactic Drugs in Patients With	
Acute Management	105	Congenital Heart Disease	125
Chronic Management	106	General Considerations for Immunoprophylaxis	127
Conclusion	109	Nonpharmacological Prevention	127
Annotated Bibliography	109	Vaccine Development	127
Self-Assessment Questions	111	Economics of Bronchiolitis	128
BRONCHIOLITIS		Cost of RSV Infections	128
Learning Objectives	117	Cost of Immunoprophylaxis	128
Introduction	117	Conclusion	129
Virology and Pathophysiology	117	Annotated Bibliography	130
Identification and Classification of Viruses		Self-Assessment Questions	133
Responsible for Illness	117	PEDIATRIC AMBULATORY CARE	
Viral Replication and Transmission	117	Learning Objectives	137
Pathophysiology	117	Introduction	137
Epidemiology and Etiology	118	Fever	137
Seasonal Outbreaks	118	Definition	137
Risk Factors	118	Pathophysiology	138
Hospitalization Rates	118	Measurement of Body Temperature	138
RSV Infection in Adults	118	Benefits of Fever	139
Nosocomial Outbreaks	119	Adverse Effects of Fever	139
Clinical Presentation and Diagnosis	119	Management	139
History and Symptoms	119	Treatment Goals	139
Physical Examination	119	Nondrug Therapy	140
Laboratory and Radiographic Findings	119	Pharmacotherapy	140
RSV Diagnostic Tests	119	Acetaminophen and Ibuprofen—Efficacy	140
Differential Diagnosis	120	Effectiveness and Dosing	140
Course and Prognosis	120	Dosage Forms and Strengths	141
Acute Illness	120	Problems with Caregiver Dosing of	
Morbidity and Mortality	120	Acetaminophen and Ibuprofen	142
Association with Asthma	120	Adverse Effects	142
Quality Pharmaceutical Care	120	Role of the Pharmacist	143
Short-term Management	120	Otitis Media	143
Nonpharmacological Therapies	120	Definitions	143
Oxygen	120	Prevalence	143
Heliox	121	Risk Factors	143
Hydration	121	Pathophysiology	143
Pharmacological Therapies	121	Diagnosis	143
Aerosolized Bronchodilators	121	Clinical Presentation	145
General Considerations	121	Complications	145
β -Adrenergic Agonist	121	Microbiology of Otitis Media	145
Epinephrine	121	Susceptibility Studies	146
Anticholinergics	122	Treatment Goals	147
Corticosteroids	122	Nondrug Therapy	147
Ribavirin	122	Pharmacotherapy of AOM	147
Nitric Oxide	122	Use of Analgesics and Observation with	
Exogenous Surfactant	123	Antibiotic Drugs	147
Antibiotic Drugs	123	Observation	148
Treatment Plan	123	Antibiotic Drug Therapy	149
Principles of Therapy	123	Antibiotic Clinical Studies	149
Therapeutic Goals and Desired Outcomes	123	Antibiotic Drug Choice	149
Prophylaxis of RSV Infections	124	Practical Considerations of Antibiotic Drug	
Immunoprophylaxis	124	Choice	150

Adverse Effects	151
Duration of Treatment	151
Prophylaxis	151
Antihistamines and Decongestants	151
Monitoring and Follow-up	152
Prevention	152
Treatment Costs	152
Otitis Media With Effusion	152
Role of the Pharmacist	153
Immunizations	153
Definitions	153
Goals and Efficacy	154
Information Sources	154
Recommended Pediatric Immunization Schedule	155
Components of Vaccines	155
Issues Related to Vaccine Administration	157
Dosing	157
Administration Sites	157
Storage	157
Immunization Records and Adherence	158
Caregiver Perceptions of Immunization and Right of Refusal	158
Misconceptions of Contraindications	159
Adverse Effects and Contraindications	159
MMR Vaccine and Autism	160
Thimerosal and Neurologic Toxicity	162
Role of the Pharmacist in Pediatric Immunization	162
Constipation	163
Definition and Incidence	163
Etiology	163
Diagnosis and Clinical Presentation	163
Treatment Goals	164
Management	164
Nondrug Therapy	164
Education	164
Pharmacotherapy	164
Disimpaction	164
Maintenance Therapy	165
Choice of Maintenance Drugs	165
Drug Doses	165
Drug Adverse Effects	165
Treatment Outcomes and Follow-up	165
Role of the Pharmacist	166
Common Cold	167
Prevalence	167
Microbiology, Pathophysiology, and Transmission	167
Clinical Presentation and Diagnosis	169
Treatment Goals	171
Nondrug Therapy	171
Pharmacotherapy	171
Adverse Effects	172
Patient Education and Role of the Pharmacist	173
Conclusion	173
Annotated Bibliography	173
Self-Assessment Questions	175

CYSTIC FIBROSIS	
Learning Objectives	181
Introduction	181
Epidemiology	181
Genetics	181
Diagnosis	182
Sweat Chloride Test	182
Genotyping	183
Nasal Potential Difference	184
Newborn Screening	184
Clinical Manifestations	185
Respiratory Disease	185
Pathophysiology	185
Airway Obstruction, Infection, and Inflammation	185
Microbiology of CF Airways	185
<i>Pseudomonas aeruginosa</i>	185
<i>Burkholderia cepacia</i>	187
<i>Aspergillus fumigatus</i>	187
Clinical Presentation	187
Chronic Bronchitis	187
Acute Pulmonary Exacerbations	188
Chronic Sinusitis	188
Assessment/Monitoring of Respiratory Disease	188
Treatment of Respiratory Disease	188
Airway Clearance Therapy	188
Mucoactive Agents	188
<i>N</i> -acetylcysteine	188
Dornase alfa	189
Hypertonic Saline	189
Bronchodilators	189
Managing Infection	189
Pulmonary Exacerbations	190
Antibiotic Drug Selection	190
Antibiotic Drug Dosing	190
Pharmacokinetics	190
Monitoring Antibiotic Drug Therapy	192
Chronic Maintenance Therapy	192
Anti-inflammatory Drugs	194
Allergic Bronchopulmonary Aspergillosis	194
Lung Transplantation	194
Gastrointestinal Disease	195
Pathophysiology	195
Clinical Manifestations	195
Malabsorption	195
Pancreatitis and Diabetes	195
Meconium Ileus and Distal Intestinal Obstruction Syndrome	195
Hepatobiliary Disease	195
Assessment and Monitoring	196
Pharmacological Therapy	196
Malabsorption and Malnutrition	196
Pancreatic Enzymes	196
Vitamin Supplementation	197
Dietary Intake	198
Appetite Stimulants	198

Distal Intestinal Obstruction Syndrome	198
Hepatobiliary Disease	198
Cystic Fibrosis-related Diabetes	198
Pathophysiology	198
Assessment and Monitoring	199
Treatment	199
Bone Health in CF	200
Pathophysiology	200
Clinical Presentation	200
Assessment/Monitoring	200
Treatment	200
Patient Access to Therapies	201
Future Therapies	202
Restore Ion Transport	202
CFTR Protein Rescue	202
Gene Therapy	202
Therapies Directed Against Airway Obstruction, Infection, and Inflammation	202
Pancreatic Enzyme Replacement	203
Quality Patient Outcome Indicators	203
The Pharmacist's Role	204
Conclusion	204
Annotated Bibliography	205
Self-Assessment Questions	207

Pediatrics II

CEREBRAL PALSY

Learning Objectives	213
Introduction	213
Definition	213
Epidemiology	213
Classification of Cerebral Palsy Subtypes	214
Etiologies, Pathogenesis, and Risk Factors	216
Etiologies	216
Contributing Factors	216
Pathogenesis	217
Diagnosis	217
History, Physical, and Neurological Examinations	217
Neurological Imaging	218
Functional Assessment Tools	219
Disease Features and Complications	219
Spasticity	219
Musculoskeletal Abnormalities	220
Nutrition and Growth Deficiencies	220
Seizures	220
Pain	221
Management of Spasticity	221
Nonpharmacological Options	221
Physical and Occupational Therapy	221
Physiotherapy, Strength Training, and Orthotics	221
Neurodevelopmental Treatment	222
Conductive Education	222
Forced-use or Constraint-induced Movement Therapy	222
Therapeutic (Subthreshold) Electrical Stimulation	222

Assistive Devices	222
Surgical Therapy	222
Musculoskeletal Interventions	222
Selective Dorsal Rhizotomy	223
Hyperbaric Oxygen	223
Pharmacological Options	224
Oral Drug Therapy for Spasticity	224
Baclofen	224
Dantrolene Sodium	225
Benzodiazepines	225
Centrally Acting α_2 -Adrenergic Agonists	226
Gabapentin	226
Drugs Used for Movement Disorders	226
Parenteral Drug Therapy	227
Intrathecal Baclofen	227
Patient Screening and Trial Dosing	227
Dosing and Chronic Management	228
Benefits and Cost of Therapy	228
Complications and Precautions	229
Botulinum Toxin	229
Pharmacology	229
Pharmacodynamics	230
Appropriate Use	231
Adverse Effects	233
Contraindications and Precautions	233
Alcohol and Phenol	233
Pain Management	235
Seizure Management	236
Management of Nutritional Complications	236
Nutritional and Growth Deficiencies	236
Role of Gastrostomy Feedings	237
Social and Developmental Issues	237
Bladder and Bowel Function	237
Drooling	237
Fractures	238
Family Issues	238
Impact of Diagnosis	238
Issues in Daily Care	238
Quality Of Life and Life Expectancy	239
Conclusion	239
Annotated Bibliography	240
Self-Assessment Questions	241

PEDIATRIC ONCOLOGY

Learning Objectives	245
Introduction	245
Leukemia	246
Acute Lymphocytic Leukemia	246
Epidemiology	246
Clinical Presentation	246
Diagnosis and Classification	246
Prognostic Factors	247
Quality Pharmaceutical Care	247
Induction	248
Central Nervous System Treatment	248
Consolidation	248

Delayed Intensification/Interim Maintenance . . .	249	Epidemiology	259
Maintenance	249	Clinical Presentation	259
T-Cell Disease	249	Diagnosis	259
Relapse	249	Prognostic Factors	259
Complications	249	Quality Pharmaceutical Care	259
Late Effects	250	Chemotherapy	260
Acute Myelogenous Leukemia	251	Local Control	260
Epidemiology	251	Metastatic Disease	260
Clinical Presentation	251	Relapse	260
Diagnosis and Classification	251	Complications	260
Prognostic Factors	251	Late Effects	261
Quality Pharmaceutical Care	251	Rhabdomyosarcoma	261
Induction	251	Epidemiology	261
Consolidation/Intensification	251	Clinical Presentation	261
Relapse	252	Diagnosis and Classification	261
Complications	252	Prognostic Factors	262
Late Effects	252	Quality Pharmaceutical Care	262
Lymphoma	252	Induction/Consolidation Chemotherapy	262
Hodgkin Disease	252	Local Control	262
Epidemiology	252	Metastases	262
Clinical Presentation	252	Relapse	262
Diagnosis and Staging	252	Complications	262
Prognostic Factors	253	Late Effects	263
Quality Pharmaceutical Care	253	Wilms' Tumor	263
Chemotherapy	253	Epidemiology	263
Radiation	254	Clinical Presentation	263
Relapse	254	Diagnosis and Classification	263
Complications	254	Prognostic Factors	263
Late Effects	254	Quality Pharmaceutical Care	264
Non-Hodgkin Lymphoma	255	Local Control	264
Epidemiology	255	Induction/Consolidation Chemotherapy	264
Clinical Presentation	255	Bilateral Disease	264
Diagnosis and Staging	255	Metastatic Disease	264
Quality Pharmaceutical Care	255	Relapse	264
Burkitt's Lymphoma	255	Complications	265
Large Cell Lymphoma	256	Late Effects	265
Lymphoblastic Lymphoma	256	Neuroblastoma	265
Relapse	257	Epidemiology	265
Complications	257	Clinical Presentation	265
Late Effects	257	Diagnosis and Classification	265
Bone and Soft Tissue Sarcomas	257	Prognostic Factors	266
Ewing Sarcoma	257	Quality Pharmaceutical Care	266
Epidemiology	257	Induction Chemotherapy	266
Clinical Presentation	257	Surgery	266
Diagnosis and Classification	257	Radiation	266
Prognostic Factors	257	Stem Cell Transplantation	266
Quality Pharmaceutical Care	257	Minimal Residual Disease Therapy	266
Induction/Consolidation Chemotherapy	257	Metaiodobenzylguanidine	267
Local Control	258	Relapse	267
Metastatic Disease	258	Complications	267
Relapse	258	Late Effects	267
Novel Drugs	259	The Pharmacist's Role	268
Complications	259	Annotated Bibliography	268
Late Effects	259	Self-Assessment Questions	271
Osteosarcoma	259		

PHARMACOTHERAPY OF ADHD	
Learning Objectives	.275
Introduction	.275
Pathophysiology	.275
Epidemiology	.275
Etiology	.276
Genetics	.276
Environmental	.276
Neural Imaging and Functional Changes	.276
Neurochemical Alterations	.276
Diagnostic Criteria and Clinical Presentation	.276
Rating Scales	.277
Conners' Rating Scales-Revised	.278
IOWA Conners' Teacher Rating Scale	.278
Comorbidity and Prognosis	.278
Pharmacological Management	.279
ADHD Algorithms and Treatment Guidelines	.279
Stimulants	.279
Available Formulations	.280
Adverse Effects and Management	.283
Insomnia	.284
Anorexia	.284
Growth Retardation	.285
Behavioral Rebound	.285
Irritability	.286
Dizziness/Hypertension	.286
Hepatotoxicity	.286
Stimulant Drug Use and ADHD	.286
Nonstimulant Drugs	.286
Antidepressant Drugs	.286
Tricyclic Antidepressants	.286
Bupropion	.287
Venlafaxine	.288
Other Nonstimulant Drugs	.288
Atomoxetine	.288
α_2 -Agonists	.289
Comorbidity Management	.290
Tic Disorders	.290
Seizures	.291
Conduct Disorder	.291
Depression/Anxiety	.291
Substance Abuse	.292
Nonpharmacological Management	.292
Principles of Treatment and Education	.293
Conclusion	.293
Annotated Bibliography	.296
Self-Assessment Questions	.297